Objectives: To develop new HIV-1 fusion inhibitors with improved antiviral activities and resistance profiles, we designed two categories of artificial peptides, each containing four heptad repeats (m4HR) conjugated with a pocket-specific small molecule (pssm) or pssm and cholesterol (chol), designated pssm -m4HR or pssmm4HR -chol, respectively, and tested their anti-HIV-1 activity.
Introduction
Viruses are divided into two main categories: enveloped and non-enveloped. 1 For enveloped viruses, one or more fusion proteins are anchored to their envelope to facilitate fusion with the target cell membrane. 2 While varying greatly in terms of their molecular architectures, viruses all catalyse membrane fusion via a common mechanism. 3 In the class I fusion proteins used by enveloped viruses, such as HIV-1 and influenza A viruses, a general structure, termed the coiled-coil six-helix bundle (6HB), lowers the large energy barrier of fusion to draw the viral and cellular membranes together to enable host cell infection. 3, 4 For entry, HIV-1 requires envelope glycoproteins (Env), which are synthesized as the fusion-incompetent precursor gp160. Then, the initially produced gp160 is cleaved by a cellular protease to yield the surface (gp120) and transmembrane (gp41) subunits. 5, 6 Unlike haemagglutinin 1 (HA1) and haemagglutinin 2 (HA2) in influenza viruses, which are connected by a disulphide bond, the surface subunit gp120 and the transmembrane subunit gp41 are non-covalently associated. After gp120 binds to its CD4 receptor and chemokine coreceptors (CCR5 or CXCR4), a series of gp120 conformational changes occurs, resulting in dissociation of the gp120 -gp41 complex. 7, 8 Like other class I transmembrane proteins, gp41 consists of an extracellular domain, a transmembrane domain and a cytoplasmic tail. 9 Its extracellular domain contains a fusion peptide (FP) at the N-terminus, an N-terminal heptad repeat (NHR), a C-terminal heptad repeat (CHR) and a tryptophanrich region. 10, 11 In the pre-hairpin structure, the FP inserts into the target membrane, generating a bridge between the viral and host cell membrane. The collapse into a fusogenic 6HB conformation brings the two bilayers into proximity for fusion ( Figure 1a) . 12, 13 The length of time between the pre-hairpin conformation and the hemifusion state varies depending on the virus. 4 During this time frame, inhibitors that competitively bind to either the central trimeric NHR coiled coil (N-trimer) or the CHR can prevent fusogenic 6HB formation, thus interrupting the process of membrane fusion and stopping viral infection at an early stage.
14 Enfuvirtide (generic name, enfuvirtide; brand name, Fuzeon), a 36 amino acid synthetic peptide derived from the CHR region of gp41, was approved by the US FDA for clinical use in 2003 as the only HIV-1 fusion inhibitor. 15, 16 C34 was another C-peptide fusion inhibitor and displayed greater anti-HIV-1 activity than enfuvirtide. However, C34 has only been used as a laboratory tool to study the mechanism of the HIV-1 Env-mediated membrane fusion due to its poor solubility under physiological conditions. 8 X-ray crystallographic studies of the N36/C34 complex have shown the presence of a critical and highly conserved hydrophobic deep pocket on the surface of the gp41 N-trimer. Consequently, this pocket has since become an attractive target for discovering non-peptide fusion inhibitors. 17, 18 Some synthetic small-molecule fusion inhibitors, such as N-(4-carboxy-3-hydroxyphenyl)-2, 5-dimethylpyrrole (NB-2) and N-(3-carboxy-4-hydroxyphenyl)-2,5-dimethylpyrrole (A 12 ), inhibit HIV-1 replication at a micromolar level (Figure 1b) . 19, 20 In addition, previous reports have indicated that cholesterol-conjugated peptides could interact with the prehairpin intermediate before the FP embeds in the target membrane, thus targeting an earlier stage of the time frame. 21, 22 Although enfuvirtide efficiently inhibits the replication of HIV-1 strains that are either wild-type or resistant to reverse transcriptase inhibitors and protease inhibitors, it can easily induce drug-resistant . Enfuvirtide and C34 are derived from the HIV-1 gp41 CHR. Both C34 and PBD -m4HR contain a PBD (underlined), through which they can interact with the conserved hydrophobic pocket in the gp41 N-trimer. (b) NB-2 and A 12 are N-substituted pyrroles that were designed to target the gp41 pocket. Based on their structures, four N-substituted pyrrole derivatives were designed, in which carboxylic acid groups (in italics) were introduced and used for conjugation with the m4HR peptide. (c) Schematic representation of our designed small-molecule -peptide conjugates. In series A, the artificial peptide (m4HR) was conjugated with a pocket-specific small molecule. In series B, a cholesterol group was further coupled to the C-terminus of conjugates in series A.
HIV-1 variants and result in increasing failure rates in enfuvirtide therapy. 23, 24 We hypothesize that infection by enfuvirtidesusceptible and -resistant HIV-1 strains could be prevented by synthetically designed peptide sequences that are non-homologous with naturally occurring peptides conjugated with one or two small molecules. Here we designed two such categories of smallmolecule-peptide conjugates, designated pssm-m4HR (pssm¼-pocket-specific small molecule,) and pssm -m4HR -chol (chol ¼ cholesterol), in which the m4HR (four heptad repeats) sequence is based on our previously designed C-peptide fusion inhibitor PBD-m4HR (PBD¼pocket-binding domain) (Figure 1c) . 25 The conjugated peptides were tested as inhibitors of HIV-1 Env-mediated cell -cell fusion and laboratory-adapted HIV-1 replication. Moreover, the conjugates with high potency, such as 5a and 5b, were tested against primary HIV-1 isolates and enfuvirtideresistant HIV-1 strains. Furthermore, computational modelling studies were performed to better understand the bioassay results and the nature of the interaction between the conjugates and their target. Therefore, this study provides lead compounds for the rational design of novel antiviral conjugates with highly potent antiviral activity against a broad spectrum of HIV-1 strains, including those highly resistant to enfuvirtide. This approach can also be applied for developing viral fusion inhibitors against other enveloped viruses with class I fusion proteins.
Materials and methods

Peptide synthesis
Peptides were synthesized using a Liberty TM automated microwave peptide synthesizer (CEM Co., Matthews, NC, USA) with a standard solid-phase N-(9-fluorenyl)methoxycarbonyl (Fmoc) chemistry protocol. All protected amino acids used were purchased from GL Biochem Ltd (Shanghai, China). Rink Amide resin and 4-methyl benzhydrylamine (MBHA) resin (0.38 -0.45 mmol/g, Nankai Hecheng S&T Co. Ltd, Tianjin, China) were used. Coupling of the amino acids was achieved using O-benzotriazol-1-yl-N,N,N ′ ,N ′ -tetramethyluronium hexafluorophosphate (HBTU, GL Biochem, Shanghai, China) and diisopropylethylamine (DIEA, Acrose) as an activator and an active base, respectively, in N,N-dimethylformamide (DMF) solution. The Fmoc protection group was removed using 20% piperidine/ DMF. Between every coupling or Fmoc removal, the resin was washed five times with DMF and three times with dichloromethane. The carboxyl termini were amidated upon cleavage from the resin, and the amino termini were capped with acetic acid anhydride. The peptides were cleaved from the Rink Amide resin and deprotected with Reagent K, which contained 82.5% trifluoroacetic acid (TFA), 5% thioanisole, 5% m-cresol, 5% water and 2.5% ethanedithiol. Moreover, the peptides were cleaved from the MBHA resin and deprotected with Reagent M, which contained 85% hydrogen fluoride (HF), 10% ethanedithiol and 5% thioanisole. The crude peptide products were precipitated with cold diethyl ether, lyophilized, and purified by preparative reverse-phase HPLC using a Waters preparative HPLC system (PrepLC 4000): gradient elution of 30% -50% solvent B in solvent A (0.1% TFA in H 2 O, solvent A; 0.1% TFA in 70% CH 3 CN/H 2 O, solvent B) over 60 min at 16 mL/min on a Waters X-bridge C8, 10 mm, 19.5 mm×250 mm column. Analytical reverse-phase HPLC was performed on an RP-C8 column (Zorbax Eclipse XDB-C8, 5 mm, 4.6 mm×150 mm) with gradient elution of 5% -100% solvent B in solvent A over 25 min at a flow rate of 1 mL/min. Compounds were detected by UV absorption at 220 nm with a Shimadzu SPD-10A detector. All peptides were purified to .95% purity. The molecular weight of the peptides was confirmed by matrix-assisted laser desorption/ionization -time of flight mass spectrometry (MALDI-TOF-MS; Autoflex III, Bruker Daltonics).
Conjugate synthesis
The conjugated peptides in series A were synthesized on Rink Amide resin or MBHA resin by using the Fmoc strategy. For Aoc and Noc, 26 a carboxymethyl group was introduced to the phenolic group of A 12 and NB-2, respectively, and this carboxylic acid group was coupled to the N-terminus of the m4HR peptide. A tert-butyl ester was used to protect the carboxyl group on the benzene ring. The Aoc/Noc-m4HR conjugates were cleaved from the resin with Reagent K. All protection groups on m4HR, including the tert-butyl group on the non-peptide moiety, were removed. For Apc and Npc, a carboxylic acid group was introduced to the pyrrole group so that it could be conjugated with the m4HR sequence, and a benzyl group protected the carboxyl group on the benzene ring. The Apc/Npc-m4HR conjugates were cleaved from the resin with Reagent M. The benzyl group on the small molecule and all the protection groups on m4HR were removed. In this series, the C-terminus of the conjugated peptides was amidated. Conjugates in series B were initially synthesized using the same strategies as compounds in series A. However, a cysteine (Cys) residue was added to the C-terminus of pssm-m4HR conjugates through a b-alanine spacer. At the end of the synthesis, the dry peptide resins were cleaved with Reagent K or M, and the crude Cys precursors were purified by reverse-phase HPLC as described above. Thereafter, conjugates in series B were prepared by chemoselective thioether conjugation between the Cys precursors and the cholesterol derivative ( Figure 2) . 27 In brief, 20 mg of purified Cys peptide precursor was dissolved in 300 mL of DMSO, to which 1.5 mg of cholest-5-en-3-yl bromoacetate dissolved in 200 mL of THF was added. Then, 7 mL of DIEA was added to the mixture, which was left stirring at room temperature. The reaction was monitored by analytical reverse-phase HPLC with a Phenomenex Jupiter C4 column (150 mm×4.6 mm, 5 mm) using 0.1% TFA in water (A) and 0.1% TFA in 90% CH 3 CN/H 2 O (B) as the eluents, and the following linear gradients: 50%-80% (B) in 5 min to 100% (B) in 3 min, washing step at 100% (B) for 20 min, flow 1 mL/min. After 4 h of incubation, the reaction was complete and the resulting conjugated peptide was purified to .95% purity as described above and confirmed by MALDI-TOF-MS.
Cell-cell fusion assay
Cell -cell fusion assays were performed as previously described. 28 HL2/3 cells were obtained through the NIH AIDS Reagent Program (contributed by Drs Barbara K. Felber and George N. Pavlakis at the National Cancer Institute, Frederick, MD, USA); these cells stably express HIV Gag, Env, Tat, Rev and Nef proteins. TZM-bl cells were also obtained through the NIH AIDS Reagent Program (contributed by Drs John C. Kappes and Xiaoyun Wu); they stably express large amounts of CD4 and CCR5. TZM-bl cells (2.5×10 4 /well) and HL2/3 cells (7.5×10 4 /well) were coincubated in 96-well plates (Corning Costar) at 378C in 5% CO 2 in the presence of different concentrations of inhibitors. After incubation for 6-8 h, the medium was aspirated, the cells were washed and lysed, and luciferase activity was measured using the Luciferase Assay System (Promega, Madison, WI) on a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA).
HIV-1 infection assay
To measure the inhibitory activity of the peptides on infection with HIV-1 IIIB and enfuvirtide-resistant HIV-1 strains, 1×10 4 MT-2 cells were infected with 100 TCID 50 of a virus in the presence or absence of the peptides at graded concentrations. On the 4th day post-infection, the culture supernatants were collected for detection of p24 antigen using ELISA. Percentage inhibition by the peptides and 50% inhibitory concentration (IC 50 ) values were calculated using Calcusyn software. 29, 30 The inhibitory activity of the peptides on infection by primary HIV-1 isolates in CEMx174 5.25M7 cells was determined as previously described. 31 In brief, 50 mL of a peptide at a grade concentration was incubated with an equal volume of a primary HIV-1 isolate at an moi of 0.01 at 378C for Artificial peptide conjugates as potent HIV-1 fusion inhibitors 1539 JAC 5 / mL). After incubation at 378C overnight, the culture medium was replaced with fresh medium without antibody. On day 7 post-infection, the culture supernatants were collected for testing for p24 as described above. Percentage inhibition by the peptides and IC 50 values were calculated as described above. 29, 30 Cytotoxicity assay
The in vitro cytotoxicity of conjugated peptides towards virus target cells (MT-2) was measured using the XTT assay. Briefly, 100 mL aliquots of conjugates at graded concentrations were added to equal volumes of cells (5×10 5 /mL) in wells of 96-well plates. After incubation at 378C for 4 days, 50 mL of XTT solution (1 mg/mL) containing 0.02 mM phenazine methosulphate was added. After 4 h, the absorbance at 450 nm (A 450 ) was measured using an ELISA reader. The 50% cytotoxic concentration (CC 50 ) was calculated using CalcuSyn software.
Computational modelling
The conformation of the artificially designed conjugated peptides was studied by molecular dynamics simulation using AMBER 8.0 on a SGI Altix 350 workstation (Fremont, CA). 32 Molecular models were constructed using SWISS-MODEL web servers based on the structure of the N36/ SC34EK complex (PDB: 2Z2T). The peptide was immersed in a rectangular box with the TIP3P water model before energy minimization. Two stages of minimization and two stages of equilibration were conducted to obtain an initial state for a further 5 nm simulation, which was conducted at a constant temperature of 300 K and a constant pressure of 1 atm, without restraints on the system. The coordinates of the entire system at each timepoint (10 ps) of the output trajectories were saved. PBTOT/GBTOT was calculated using the mm_pbsa.pl program.
Results and discussion
Design
Previously, we utilized a structure-based rational design strategy based on the HIV-1 gp41 NHR and CHR interaction to generate a highly potent HIV-1 fusion inhibitor, namely PBD-m4HR. It was an artificially designed peptide sequence and exhibited a low nanomolar IC 50 value against HIV-1 Env-mediated cell -cell fusion. 25, 33 PBD-m4HR contains a PBD that projects into a primary cavity of gp41. This highly conserved hydrophobic pocket is also an attractive target for small-molecule HIV-1 fusion inhibitors. Two N-substituted pyrrole derivatives, NB-2 and A 12 , target this cavity and show micromolar antiviral activities. 20, 34 The structureactivity relationship and computational docking analysis of these two N-carboxyphenylpyrrole derivatives indicated the following: (i) the negatively charged carboxyl group formed a strong salt bridge with either the positively charged Lys574 or Arg579 around the pocket; (ii) the hydrophobic pyrrole ring underwent a hydrophobic interaction with the gp41 pocket; and (iii) the phenolic group contributed less to its overall binding affinity and may be a favourable position for modification. 20, 35 Therefore, we previously designed and synthesized four phenylpyrroles
with different inhibitory activities against HIV-1 Env-mediated cell -cell fusion (Figure 1b) . 26 Following the logic described above, we designed the first series of small-molecule -peptide conjugates. In this series (series A: pssm -m4HR), N-substituted pyrrole derivatives (pssm) were conjugated with the m4HR sequence through one of the flexible linkers with different lengths and flexibilities, including b-alanine, 6-aminohexanoic acid and tetraethylene glycol.
Due to the limited time window and the diffusion-limited inhibition of HIV-1-virus cell membrane fusion, there is a potency plateau for fusion inhibitors. 36 On this plateau, the potency of fusion inhibitors cannot be increased because of their inability to arrive at the target within the available time frame. Increasing an inhibitor's concentration in the fusion-triggered location is, however, a possible way to improve this otherwise limited potency. In the Wang et al.
membrane-proximal external region (MPER) of HIV-1, tryptophan and aromatic residues are enriched. 16, 37 This region interacts with lipid rafts in the membrane to stabilize the post-fusion structure. The cholesterol group, as an ideal membrane anchor, may also interact with lipid rafts to increase the concentration of inhibitors near the cell surface and further enhance the inhibitory activity of the conjugates. 27 Therefore, we designed the second series of small-molecule -peptide conjugates (series B: pssm -m4HR -chol). In this series, the pocket-specific small molecule and a cholesterol group were conjugated to the N-and C-termini of the m4HR sequence, respectively, at the same time (Figure 1c ).
Inhibitory activities of the small molecule -artificially designed peptide conjugates on HIV-1 Env-mediated cell -cell fusion
We used a cell-cell fusion assay to measure the inhibitory activities of the conjugates and their activities are shown in Table 1 . The artificially designed peptide m4HR had an IC 50 value of 36 910 nM. After N-carboxylphenylpyrrole derivatives (pssm) were conjugated to the m4HR sequence through a flexible linker, all the conjugates exhibited dramatically increased inhibitory activities, with IC 50 values ranging between 396 and 3462 nM, about a 10-to 90-fold increase compared with the unconjugated m4HR peptide. Compound 1a, the most potent conjugate in series A, exhibited an IC 50 value of 0.3 mM. These results demonstrated a co-operative effect between N-substituted pyrrole derivatives and the artificially designed m4HR sequence, which target the pocket and the groove on the gp41 NHR, respectively. In addition, this effect was strengthened by the increased specificity of the non-peptide moiety because the Aoc/Noc -m4HR conjugates were more potent than the Apc/Npc -m4HR conjugates. Furthermore, we explored the influence of the linker's length and flexibility on the hybrid molecules. We selected two kinds of linkers: n-alkanes, such as b-alanine and 6-aminohexanoic acid; and aliphatic ethers, such as tetraethylene glycol. Comparisons among conjugates with different linkers, such as 1a (IC 50 396 nM), 1b (IC 50 466 nM) and 1c (IC 50 536 nM), indicated that the length and flexibility of the linker did not significantly affect the potency of the conjugates.
We next turned our attention to improving the hybrid molecule's potency by increasing an inhibitor's concentration in the fusion-triggered location. To reach this goal, we further conjugated a cholesterol group to the C-terminus of conjugates in series A. Cholesterol conjugation dramatically improved pssm -m4HR potency as much as 200-fold. The most effective compound, 5a, had an IC 50 value of 8.3 nM, reaching the potency of the clinically used HIV-1 fusion inhibitor enfuvirtide. We also covalently linked cholesterol to the m4HR peptide as a control. As shown in Table 1 , compound 6 (m4HR -chol) displayed an IC 50 value of 57.2 nM, 6-fold less potent than compound 5a (pssm -m4HR -chol). These results suggested that the 'specific' interactions between pssm and the primary cavity, between Artificial peptide conjugates as potent HIV-1 fusion inhibitors m4HR and NHR-trimer, and the 'non-specific' interaction between cholesterol and the target cell membrane are all important for the anti-HIV-1 activity of the pssm -peptide -cholesterol conjugates.
Inhibitory activities of the series A and B conjugates on infection by laboratory-adapted and primary HIV-1 isolates
Subsequently, we determined the activities of the artificially designed peptide conjugates against infection using a laboratoryadapted HIV-1 IIIB strain. The inhibitory activities of peptide conjugates against HIV-1 IIIB replication in MT-2 cells were assessed using a p24 ELISA as previously described. 19 As shown in Table 2 , compounds 1-4a all showed inhibitory activities against HIV-1 IIIB replication at submicromolar levels. In series B, 5a-d all inhibited HIV IIIB infection at low nanomolar levels, consistent with the cell-cell fusion assay. The most active compound, 5a, had an IC 50 value of 7.16+0.43 nM, providing a 9-fold increase in potency compared with enfuvirtide. We further tested the inhibitory activity of compound 5a and 5b on infection by the primary HIV-1 isolates in CEMx174 5.25M7 cells. As shown in Table 3 , compounds 5a and 5b effectively inhibited infection by R5 HIV-1 subtypes B (94US_33931N), C (93IN101) and A/E (92TH009), with IC 50 values in the range of 10 -60 nM, suggesting that these peptides possess broad anti-HIV-1 activity. We also tested the cytotoxicities of these compounds on MT-2 cells using an XTT cytotoxicity assay. The CC 50 values of compounds 1-4a were all .230 mM, with selectivity indices (SIs) .100. The CC 50 values of compounds 5a -d were in the range of 19-86 mM, with SI values ranging from 116 to 7263.
Conjugated peptides are highly potent against enfuvirtide-resistant HIV-1 strains
Rapid emergence of resistance is the key obstacle in developing antiviral drugs. Enfuvirtide suppresses the replication of HIV-1 variants with multiple resistance to reverse transcriptase inhibitors or protease inhibitors. 38 However, it also rapidly induces enfuvirtide-resistant HIV-1 strains after clinical use. We suspected that this was because enfuvirtide was derived from the natural CHR sequence. Although it meets the requirement of resembling the natural target, the genetic barrier to the emergence of a resistant virus is low. Therefore, we evaluated whether our artificial sequence could be effective against infection by enfuvirtidesusceptible and -resistant HIV-1 strains. As shown in Table 4 , a panel of HIV-1 NL4-3 mutants, including one enfuvirtidesusceptible strain and five enfuvirtide-resistant strains, was used in our experiments. Enfuvirtide was inactive against enfuvirtideresistant strains, even at a concentration as high as 2000 nM. However, 5a and 5b were highly potent against both enfuvirtidesusceptible and -resistant strains, with IC 50 values ranging from 40 to 230 nM. Previously, it was reported that mutations in the NHR region of gp41 (amino acids 36 -45: GIVQQQNNLL) were the main factor that led to enfuvirtide therapy failure. 39, 40 Enfuvirtide contains a helix-zone binding domain and a lipidbinding domain. C34 contains a PBD and a helix zone binding domain. Thus, enfuvirtide and C34 share the same helix zone binding sequence and they both inhibit HIV-1 fusion by binding this domain to the helix zone sequences in NHR, including the GIV motif. Therefore, mutations in the GIV motif can induce resistance to both enfuvirtide and C34. However, C34 contains a PBD through which C34 can interact with the primary cavity in the gp41 NHR and this interaction may partially compensate for the decreased binding of C34 to NHR. 41 Consequently, C34 is much more effective against enfuvirtide-resistant strains than enfuvirtide. Unlike enfuvirtide and C34, the peptide moiety in our conjugates is an artificially designed sequence that is non-homologous with naturally occurring peptide and protein sequences. Furthermore, the pocket-specific moiety mimics the PBD to specifically interact with the NHR pocket and a cholesterol group nonspecifically interacts with the target cell membrane. Thus, mutations of the GIV motif would have little effect on the interaction between conjugates and their targets. Therefore, the novel scaffold small-molecule -peptide conjugates with high efficacy against both enfuvirtide-susceptible and -resistant HIV-1 strains could be developed into a new drug to treat patients who fail to respond to the current enfuvirtide therapy.
Function of cholesterol modification as determined by a prime/wash assay in cell -cell membrane fusion
To illustrate the key mechanism of action of the cholesterol conjugates on cell-cell fusion, a prime/wash assay was performed. Compounds were tested in triplicate, and the data are presented as mean+SD.
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First, conjugates 1a, 5a and 6, as well as enfuvirtide and C34 control, were incubated with TZM-b1 cells at 378C for 1 h, followed by washing. Then, HL2/3 cells were added to initiate infection. After incubation for 48 h, we calculated the IC 50 values of the peptide with or without washing to evaluate the ability of residual peptides to inhibit cell -cell fusion. As shown in Table 5 , the antiviral activity of C34 was dramatically decreased (.2000-fold) as a result of its insufficient interaction with the cell membrane. In addition, the inhibitory activity of 1a, similar to that of C34, decreased .200-fold. Unlike C34, enfuvirtide could interact with the target cell membrane. Therefore, its inhibitory activity on cell -cell fusion was decreased only 175-fold in the wash assay. Strikingly, 5a and 6 with cholesterol as an anchor showed a moderate 8-fold decrease in potency. These results indicated that the cholesterol group, as a membrane-localizing group, had strong binding affinity with the cell membrane. Because 5a could simultaneously bind both the primary pocket on the gp41 NHR and the target cell membrane, it exhibited greater potency than conjugated peptide 6.
Computational modelling
The predominant conformations of artificially designed conjugated peptides in series A were investigated with computational modelling to better understand and interpret the bioassay results and the nature of the interaction with the central trimeric NHR coiled coil. The binding free energy for the association between the predominant conformations of the designed conjugates and the NHR was estimated. Molecular dynamics simulations were conducted on the peptide complex using AMBER 8.0, based on the X-ray crystal structure of the N36/SC34EK complex (PDB: 2Z2T). From calculations of negative total binding free energy, we knew that the binding free energies of 1a (2298.71+12.41 kcal/mol) and 2a (2262.33+15.35 kcal/mol) were notably lower than that of the m4HR peptide (2211+ 16.58 kcal/mol), meaning that the complexes formed between 1a or 2a and the NHR were more stable than the m4HR peptide alone. Figure 3 shows the computational model of the complex formed between 1a (red and yellow) and the N36 coiled coil (blue) in side view. In this model, 1a and the N36 coiled coil interacted with each other in an antiparallel manner to form a stable Enfuvirtide-resistant strain. Artificial peptide conjugates as potent HIV-1 fusion inhibitors coiled coil. In addition, the conjugates adopted a fully a-helical structure. The non-peptide moiety accurately complemented with the hydrophobic pocket, while the m4HR peptide tightly bound to the hydrophobic groove on the surface of the central coiled coil (N-trimer).
Conclusions
In short, our designed artificial peptides conjugated with cholesterol and pocket-specific small molecules exhibit potent antiviral activity against a broad spectrum of laboratory-adapted and primary HIV-1 isolates, including enfuvirtide-resistant HIV-1 strains. Because they contain multiple target sites, these peptide conjugates may possess a higher genetic barrier to drug resistance than the reported HIV-1 peptide fusion inhibitors generally targeting a single site in gp41. The anti-HIV-1 activities of these peptides with artificial sequences are not expected to be neutralized by antibodies directed against natural viral sequences in HIV-1-infected hosts. This novel strategy may also be used for designing universal antiviral peptides against other viruses with class I membrane fusion proteins. 
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